Do protein supplementation increase health-related QoL in advanced chronic kidney disease? Check out the recap thread made by NephJC intern Clemens Weber
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
Summary of the STEPS trial which will be a twitter spaces discussion
Do protein supplementation increase health-related QoL in advanced chronic kidney disease? Check out the recap thread made by NephJC intern Clemens Weber
1/10 Last #NephJC we tried to answer the question whether protein supplementation increases health-related QoL 🥩💊 #TenPostNephJC
— Nephrology Journal Club (@NephJC) November 24, 2025
Read the article 👇https://t.co/tFWDcvIc3u pic.twitter.com/FtOGwSNR88